Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2007

01.07.2007

Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction

verfasst von: Kazumasa Fujitani, Jaffer A. Ajani, Christopher H. Crane, Barry W. Feig, Peter W. Pisters, Nora Janjan, Garrett L. Walsh, Stephen G. Swisher, Ara A. Vaporciyan, David Rice, Angela Welch, Jackie Baker, Josephine Faust, Paul F. Mansfield

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

ABSTRACT

Background

Significant tumor downstaging has been achieved in patients with localized gastric or gastroesophageal adenocarcinoma by induction chemotherapy and preoperative chemoradiotherapy (CTX-CTXRT). However, the influence of CTX-CTXRT on operative morbidity and mortality has not yet been clarified. The aim of the present study was to document the frequency and nature of morbidity and mortality after surgery combined with CTX-CTXRT, and identify factors predictive of postoperative complications in patients with localized gastric or gastroesophageal adenocarcinoma.

Methods

A prospectively collected database on 71 consecutive patients who underwent CTX-CTXRT at M.D. Anderson Cancer Center between January 1997 and August 2004 was reviewed. Postoperative morbidity and mortality were investigated, and risk factors for overall complications were identified by multivariate logistic regression analysis.

Results

Overall morbidity and mortality rates were 38.0% (27 patients) and 2.8% (2 patients), respectively. Age greater than 60 years [relative risk 11.3 (95% confidence interval 2.50–50.6)] and body mass index (BMI) of 26 kg/m2 or above [relative risk 4.08 (95% confidence interval 1.08 to 15.4)] were significant risk factors for overall complications.

Conclusions

CTX-CTXRT can be performed safely with an acceptable operative morbidity and a low operative mortality rate in patients with gastric or gastroesophageal cancer, with careful consideration of added risk associated with age and obesity.
Literatur
1.
Zurück zum Zitat Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80:2333–2341PubMedCrossRef Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80:2333–2341PubMedCrossRef
2.
Zurück zum Zitat Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Bergstrom R, Nyren O. Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma – a population-based study in Sweden. Br J Cancer 2000; 83:391–396PubMedCrossRef Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Bergstrom R, Nyren O. Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma – a population-based study in Sweden. Br J Cancer 2000; 83:391–396PubMedCrossRef
3.
Zurück zum Zitat Wanebo HJ, Kennedy BJ, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993; 218:583–592PubMedCrossRef Wanebo HJ, Kennedy BJ, Chmiel J, Steele Jr G, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993; 218:583–592PubMedCrossRef
4.
Zurück zum Zitat Allum W, Cunningham D, Weeden S, for the UK NCRI Upper GI Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2003; 21(Suppl):abstr 998 Allum W, Cunningham D, Weeden S, for the UK NCRI Upper GI Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2003; 21(Suppl):abstr 998
5.
Zurück zum Zitat Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22:2774–2780PubMedCrossRef Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22:2774–2780PubMedCrossRef
6.
Zurück zum Zitat Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237–1244PubMedCrossRef Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23:1237–1244PubMedCrossRef
7.
Zurück zum Zitat Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia-report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42:929–934PubMedCrossRef Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia-report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42:929–934PubMedCrossRef
8.
Zurück zum Zitat Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PWT, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8:519–524PubMedCrossRef Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PWT, Ajani JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8:519–524PubMedCrossRef
9.
Zurück zum Zitat Skoropad VY, Berdov BA, Zagrebin VM. Preoperative radiotherapy in combination with metronidazole for resectable gastric cancer: long-term results of a phase 2 study. Eur J Surg Oncol 2003; 29:166–170PubMedCrossRef Skoropad VY, Berdov BA, Zagrebin VM. Preoperative radiotherapy in combination with metronidazole for resectable gastric cancer: long-term results of a phase 2 study. Eur J Surg Oncol 2003; 29:166–170PubMedCrossRef
10.
Zurück zum Zitat Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345:745–748PubMedCrossRef Bonenkamp JJ, Songun I, Hermans J et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345:745–748PubMedCrossRef
11.
Zurück zum Zitat Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P, for the Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347:995–999PubMedCrossRef Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P, for the Surgical Cooperative Group. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996; 347:995–999PubMedCrossRef
12.
Zurück zum Zitat Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22:2767–2773PubMedCrossRef Sano T, Sasako M, Yamamoto S et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy – Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22:2767–2773PubMedCrossRef
13.
Zurück zum Zitat Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005; 92:1099–1102PubMedCrossRef Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg 2005; 92:1099–1102PubMedCrossRef
14.
Zurück zum Zitat Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126:1469–1473PubMed Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126:1469–1473PubMed
15.
Zurück zum Zitat Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L, The Italian Gastrointestinal Tumor Study Group. Total versus subtotal gastrectomy: surgical morbidity and mortality in a multicenter Italian randomized trial. Ann Surg 1997; 226:613–620PubMedCrossRef Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Crose N, Gennari L, The Italian Gastrointestinal Tumor Study Group. Total versus subtotal gastrectomy: surgical morbidity and mortality in a multicenter Italian randomized trial. Ann Surg 1997; 226:613–620PubMedCrossRef
16.
Zurück zum Zitat Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449–461PubMedCrossRef Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449–461PubMedCrossRef
17.
Zurück zum Zitat Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30:303–308PubMedCrossRef Degiuli M, Sasako M, Calgaro M et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004; 30:303–308PubMedCrossRef
18.
Zurück zum Zitat Birkmeyer JD, Siewers AE, Finlayson EVA et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128–1137PubMedCrossRef Birkmeyer JD, Siewers AE, Finlayson EVA et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128–1137PubMedCrossRef
19.
Zurück zum Zitat Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117–2127PubMedCrossRef Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117–2127PubMedCrossRef
20.
Zurück zum Zitat Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6–15PubMedCrossRef Hannan EL, Radzyner M, Rubin D, Dougherty J, Brennan MF. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery 2002; 131:6–15PubMedCrossRef
21.
Zurück zum Zitat Sasako M, for the Dutch Gastric Cancer Study Group. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84:1567–1571PubMedCrossRef Sasako M, for the Dutch Gastric Cancer Study Group. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 1997; 84:1567–1571PubMedCrossRef
22.
Zurück zum Zitat Hartgrink HH, van de Velde CJH, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004; 22:2069–2077PubMedCrossRef Hartgrink HH, van de Velde CJH, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 2004; 22:2069–2077PubMedCrossRef
23.
Zurück zum Zitat Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A , Kurita A, on behalf of the Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92:1103–1109PubMedCrossRef Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A , Kurita A, on behalf of the Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg 2005; 92:1103–1109PubMedCrossRef
24.
Zurück zum Zitat Cuschieri A, Weeden S, Fielding J et al., for the Surgical Co-operative Group. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79:1522–1530 Cuschieri A, Weeden S, Fielding J et al., for the Surgical Co-operative Group. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79:1522–1530
25.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Weeden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2005; 23(Suppl): abstr 4001 Cunningham D, Allum WH, Stenning SP, Weeden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol 2005; 23(Suppl): abstr 4001
Metadaten
Titel
Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction
verfasst von
Kazumasa Fujitani
Jaffer A. Ajani
Christopher H. Crane
Barry W. Feig
Peter W. Pisters
Nora Janjan
Garrett L. Walsh
Stephen G. Swisher
Ara A. Vaporciyan
David Rice
Angela Welch
Jackie Baker
Josephine Faust
Paul F. Mansfield
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9198-2

Weitere Artikel der Ausgabe 7/2007

Annals of Surgical Oncology 7/2007 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Traumatologische Notfälle Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.